Vita Life Sciences Limited · ASX:VLS
Vita Life Sciences — Shareholder Meeting (May 2023)
22 slides from Vita Life Sciences's shareholder meeting presentation, May 9, 2023
Slide 1: Annual General Meeting 9 May 2023
Annual General Meeting 9 May 2023
Slide 2: AGM Agenda
AGM Agenda 1. CHAIRMAN’S WELCOME ADDRESS 2. MANAGING DIRECTOR’S REVIEW 3. ORDINARY RESOLUTIONS 4. QUESTIONS & ANSWERS ANNUAL GENERAL MEETING 2023
Slide 3: Henry Townsing, Chairman
Henry Townsing Chairman Mr Townsing brings over 30 years’ experience in corporate finance and private equity. He was a Director of the Company, from 1985 to 1992, 2004 to 2009 and was reappointed a Director on 22nd December 2011. Mr Townsing was appointed as the Chairman of the Company effective 28t
Slide 4: AGM Agenda
AGM Agenda 1. CHAIRMAN’S WELCOME ADDRESS 2. MANAGING DIRECTOR’S REVIEW 3. ORDINARY RESOLUTIONS 4. QUESTIONS & ANSWERS ANNUAL GENERAL MEETING 2023
Slide 5: Andrew O’Keefe, Managing Director
Andrew O’Keefe Managing Director Mr O’Keefe was appointed Managing Director on 1st January 2017. Mr O’Keefe has over 20 years’ experience within the Australian pharmaceutical and healthcare industry. During his career Mr O’Keefe has held senior leadership positions in publicly listed companies and w
Slide 6: Synopsis of Business Operations
Synopsis of Business Operations Distribution - Across several markets; Australia, Malaysia, Singapore, China, Vietnam, Thailand and Indonesia Brands – Herbs of Gold, VitaHealth & VitaScience brands Products – 750 registered products across all markets Strong consumer demand – The Group met increased
Slide 7: Awards & Recognition
Awards & Recognition • Advantage Pharmacy Survey - Ranked Herbs of Gold 2nd in the Advantage Annual Pharmacy Voice of Customer Program 2022 (Over the Counter Benchmark Set) • Herbs of Gold awarded Supply Chain of the Year with National Pharmacies Group • Herbs of Gold awarded Go Vita Supplier of the
Slide 8: Marketing Overview
Marketing Overview ANNUAL GENERAL MEETING 2023
Slide 9: Financial Performance
Financial Performance Record Sales Pre-Tax Profit Balance sheet equity Dividend payment $66.9m, up 17% $10.7m, down 4% $36.5m, net cash $15.7m 6.00 cents/share, (without any borrowings) up 4% ANNUAL GENERAL MEETING 2023
Slide 10: Global Performance
Global Performance Australia is the single largest market with an increase of 3% to 56% in market share. 2022 revenue by geography Other Asia 3% $2.3M Australia 56% Singapore 9% $5.8M $37.3M Asia Total 44% revenue $66.9m Malaysia 32% $21.4M ANNUAL GENERAL MEETING 2023
Slide 11: Strategic priorities
Strategic priorities Our pillars BRAND BUILDING EDUCATION & INNOVATION TALENT WELLBEING OPERATIONAL LEVERAGE Key initiatives to support our pillars OVER 1400 RECRUITMENT OF NATIONAL NEW BUSINESS MODEL IN NEW ERP SYSTEM INCREASED BRANDING & PHARMACIES RANGING TRAINING TEAM 30 NEW PRODUCTS THAILAND &
Slide 12: Annual General Meeting 2023 quote
“Coming together is a beginning. Keeping together is progress. Working together is success?- Henry Ford ANNUAL GENERAL MEETING 2023 WAYVITA LIFE
Slide 13: Outlook
Outlook • The Group continues to be very well positioned to leverage market opportunities across the region. • The plans and vision for the business are strong and robust to drive future growth. • First half guidance will be provided in June. ANNUAL GENERAL MEETING 2023
Slide 14: AGM Agenda
AGM Agenda 1. CHAIRMAN’S WELCOME ADDRESS 2. MANAGING DIRECTOR’S REVIEW 3. ORDINARY RESOLUTIONS 4. QUESTIONS & ANSWERS ANNUAL GENERAL MEETING 2023
Slide 15: Ordinary Resolutions
Ordinary Resolutions 1. Remuneration Report 2. Re-election of Director – Jack Teoh 3. Re-election of Director- Greg Ralph (Now Withdrawn) 4. Share buy back 5. Re-election of Director- Henry Townsing ANNUAL GENERAL MEETING 2023
Slide 16: Proxy-Resolution 1
Proxy-Resolution 1 PROXY’S RESOLUTIONS IN FAVOUR AGAINST EXCLUDED DISCRETION 1) Adoption of the Remuneration Report 11,917,659 51,364 14,720,908 12,746,799 ANNUAL GENERAL MEETING 2023
Slide 17: Proxy-Resolution 2
Proxy-Resolution 2 PROXY’S RESOLUTIONS IN FAVOUR AGAINST EXCLUDED DISCRETION Re-election of Director 2) 16,148,547 24,468 14,830,022 8,154,218 (Jack Teoh) ANNUAL GENERAL MEETING 2023
Slide 18: Proxy-Resolution 3
Proxy-Resolution 3 PROXY’S RESOLUTIONS IN FAVOUR AGAINST EXCLUDED DISCRETION Re-election of Director 3) 14,736,944 3,468 22,483,329 - (Gregory Ralph) ANNUAL GENERAL MEETING 2023
Slide 19: Proxy-Resolution 4
Proxy-Resolution 4 PROXY’S RESOLUTIONS IN FAVOUR AGAINST EXCLUDED DISCRETION 4) Share buy-back 24,431,097 2,500 15,002,383 - ANNUAL GENERAL MEETING 2023
Slide 20: Proxy
Proxy PROXY’S RESOLUTIONS IN FAVOUR AGAINST EXCLUDED DISCRETION 1) Adoption of the Remuneration Report 11,817,659 51,364 14,720,908 12,746,799 Re-election of Director 2) 16,148,547 24,468 14,830,022 8,154,218 (Jack Teoh) Re-election of Director - 3) 14,736,944 3,468 22,483,329 (Gregory Ralph) 4) Sha
Slide 21: AGM Agenda
AGM Agenda 1. CHAIRMAN’S WELCOME ADDRESS 2. MANAGING DIRECTOR’S REVIEW 3. ORDINARY RESOLUTIONS 4. QUESTIONS & ANSWERS ANNUAL GENERAL MEETING 2023
Slide 22: Disclaimer
Disclaimer This document has been prepared by Vita Life Sciences Limited (Vita Life Sciences) and comprises written material/slides for a presentation concerning Vita Life Sciences. The presentation is for information purposes only and does not constitute or form part of any offer or invitation to a